Cargando…

Re-stratification of patients with copy-number low endometrial cancer by clinicopathological characteristics

OBJECTIVE: To stratify patients with copy-number low (CNL) endometrial cancer (EC) by clinicopathological characteristics. METHODS: EC patients who underwent surgery between June 2018 and June 2022 at Peking University People’s Hospital were included and further classified according to TCGA molecula...

Descripción completa

Detalles Bibliográficos
Autores principales: Liwei, Li, He, Li, Yibo, Dai, Luyang, Zhao, Zhihui, Shen, Nan, Kang, Danhua, Shen, Junzhu, Wang, Zhiqi, Wang, Jianliu, Wang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589940/
https://www.ncbi.nlm.nih.gov/pubmed/37865800
http://dx.doi.org/10.1186/s12957-023-03229-w
_version_ 1785123891823247360
author Liwei, Li
He, Li
Yibo, Dai
Luyang, Zhao
Zhihui, Shen
Nan, Kang
Danhua, Shen
Junzhu, Wang
Zhiqi, Wang
Jianliu, Wang
author_facet Liwei, Li
He, Li
Yibo, Dai
Luyang, Zhao
Zhihui, Shen
Nan, Kang
Danhua, Shen
Junzhu, Wang
Zhiqi, Wang
Jianliu, Wang
author_sort Liwei, Li
collection PubMed
description OBJECTIVE: To stratify patients with copy-number low (CNL) endometrial cancer (EC) by clinicopathological characteristics. METHODS: EC patients who underwent surgery between June 2018 and June 2022 at Peking University People’s Hospital were included and further classified according to TCGA molecular subtyping: POLE ultramutated, microsatellite instability high (MSI-H), CNL, and copy-number high (CNH). Clinicopathological characteristics and prognosis of CNL patients were retrospectively reviewed. The Cox proportional hazards regression model was applied to perform univariate and multivariate analysis, and independent risk factors were identified. Differentially expressed genes (DEGs) according to overall survival (OS) were screened based on the transcriptome of CNL cases from the TCGA program. Finally, a nomogram was established, with an accuracy analysis performed. RESULTS: (1) A total of 279 EC patients were included, of whom 168 (60.2%) were in the CNL group. A total of 21 patients had recurrence and 6 patients deceased, and no significant difference in recurrence-free survival (RFS) was exhibited among the four molecular subtypes (P = 0.104), but that in overall survival (OS) was statistically significant (P = 0.036). (2) CNL patients were divided into recurrence and non-recurrence groups, and significant differences (P < 0.05) were found between the two groups in terms of pathological subtype, FIGO stage, ER, PR, glycated hemoglobin (HbA1c), and high-density lipoprotein cholesterol (HDL-C). All the above factors were included in univariate and multivariate Cox regression models, among which pathological subtype, PR, and HDL-C were statistically different (P < 0.05), resulting in three independent risk factors for the prognosis of patients in the CNL group. (3) By comparing the transcriptome of tumor tissues between living and deceased CNL patients from the TCGA database, 903 (4.4%) DEGs were screened, with four lipid metabolism pathways significantly enriched. Finally, a nomogram was established, and internal cross-validation was performed, showing good discrimination accuracy with an AUC of 0.831 and a C-index of 0.748 (95% CI 0.444–1.052). (4) According to the established nomogram and the median total score (85.89), patients were divided into the high score group (n = 85) and low score group (n = 83), and the 8 patients with recurrence were all in the high score group. Survival analysis was performed between the two groups, and the difference in RFS was statistically significant (P = 0.010). CONCLUSION: In the CNL group of EC patients, pathological subtype, PR, and HDL-C were independent prognostic risk factors, the nomogram established based upon which had a good predictive ability for the recurrence risk of patients with CNL EC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-023-03229-w.
format Online
Article
Text
id pubmed-10589940
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105899402023-10-22 Re-stratification of patients with copy-number low endometrial cancer by clinicopathological characteristics Liwei, Li He, Li Yibo, Dai Luyang, Zhao Zhihui, Shen Nan, Kang Danhua, Shen Junzhu, Wang Zhiqi, Wang Jianliu, Wang World J Surg Oncol Research OBJECTIVE: To stratify patients with copy-number low (CNL) endometrial cancer (EC) by clinicopathological characteristics. METHODS: EC patients who underwent surgery between June 2018 and June 2022 at Peking University People’s Hospital were included and further classified according to TCGA molecular subtyping: POLE ultramutated, microsatellite instability high (MSI-H), CNL, and copy-number high (CNH). Clinicopathological characteristics and prognosis of CNL patients were retrospectively reviewed. The Cox proportional hazards regression model was applied to perform univariate and multivariate analysis, and independent risk factors were identified. Differentially expressed genes (DEGs) according to overall survival (OS) were screened based on the transcriptome of CNL cases from the TCGA program. Finally, a nomogram was established, with an accuracy analysis performed. RESULTS: (1) A total of 279 EC patients were included, of whom 168 (60.2%) were in the CNL group. A total of 21 patients had recurrence and 6 patients deceased, and no significant difference in recurrence-free survival (RFS) was exhibited among the four molecular subtypes (P = 0.104), but that in overall survival (OS) was statistically significant (P = 0.036). (2) CNL patients were divided into recurrence and non-recurrence groups, and significant differences (P < 0.05) were found between the two groups in terms of pathological subtype, FIGO stage, ER, PR, glycated hemoglobin (HbA1c), and high-density lipoprotein cholesterol (HDL-C). All the above factors were included in univariate and multivariate Cox regression models, among which pathological subtype, PR, and HDL-C were statistically different (P < 0.05), resulting in three independent risk factors for the prognosis of patients in the CNL group. (3) By comparing the transcriptome of tumor tissues between living and deceased CNL patients from the TCGA database, 903 (4.4%) DEGs were screened, with four lipid metabolism pathways significantly enriched. Finally, a nomogram was established, and internal cross-validation was performed, showing good discrimination accuracy with an AUC of 0.831 and a C-index of 0.748 (95% CI 0.444–1.052). (4) According to the established nomogram and the median total score (85.89), patients were divided into the high score group (n = 85) and low score group (n = 83), and the 8 patients with recurrence were all in the high score group. Survival analysis was performed between the two groups, and the difference in RFS was statistically significant (P = 0.010). CONCLUSION: In the CNL group of EC patients, pathological subtype, PR, and HDL-C were independent prognostic risk factors, the nomogram established based upon which had a good predictive ability for the recurrence risk of patients with CNL EC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-023-03229-w. BioMed Central 2023-10-21 /pmc/articles/PMC10589940/ /pubmed/37865800 http://dx.doi.org/10.1186/s12957-023-03229-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liwei, Li
He, Li
Yibo, Dai
Luyang, Zhao
Zhihui, Shen
Nan, Kang
Danhua, Shen
Junzhu, Wang
Zhiqi, Wang
Jianliu, Wang
Re-stratification of patients with copy-number low endometrial cancer by clinicopathological characteristics
title Re-stratification of patients with copy-number low endometrial cancer by clinicopathological characteristics
title_full Re-stratification of patients with copy-number low endometrial cancer by clinicopathological characteristics
title_fullStr Re-stratification of patients with copy-number low endometrial cancer by clinicopathological characteristics
title_full_unstemmed Re-stratification of patients with copy-number low endometrial cancer by clinicopathological characteristics
title_short Re-stratification of patients with copy-number low endometrial cancer by clinicopathological characteristics
title_sort re-stratification of patients with copy-number low endometrial cancer by clinicopathological characteristics
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589940/
https://www.ncbi.nlm.nih.gov/pubmed/37865800
http://dx.doi.org/10.1186/s12957-023-03229-w
work_keys_str_mv AT liweili restratificationofpatientswithcopynumberlowendometrialcancerbyclinicopathologicalcharacteristics
AT heli restratificationofpatientswithcopynumberlowendometrialcancerbyclinicopathologicalcharacteristics
AT yibodai restratificationofpatientswithcopynumberlowendometrialcancerbyclinicopathologicalcharacteristics
AT luyangzhao restratificationofpatientswithcopynumberlowendometrialcancerbyclinicopathologicalcharacteristics
AT zhihuishen restratificationofpatientswithcopynumberlowendometrialcancerbyclinicopathologicalcharacteristics
AT nankang restratificationofpatientswithcopynumberlowendometrialcancerbyclinicopathologicalcharacteristics
AT danhuashen restratificationofpatientswithcopynumberlowendometrialcancerbyclinicopathologicalcharacteristics
AT junzhuwang restratificationofpatientswithcopynumberlowendometrialcancerbyclinicopathologicalcharacteristics
AT zhiqiwang restratificationofpatientswithcopynumberlowendometrialcancerbyclinicopathologicalcharacteristics
AT jianliuwang restratificationofpatientswithcopynumberlowendometrialcancerbyclinicopathologicalcharacteristics